言語を選択

TREM-1

TREM-1 詳細

英語名	Triggering receptor expressed on myeloid cells 1	市販薬剤の数	0
治験薬の数	6	ターゲットの別称	Triggering Receptor Expressed On Myeloid Cells 1，CD354 Antigen，Triggering Receptor Expressed on Myeloid Cells-1，TREM-1，TREM1，CD354，Triggering receptor expressed on monocytes 1
研究＆開発段階	Phase 2 Clinical

英語名	Triggering receptor expressed on myeloid cells 1
ターゲットの別称	Triggering Receptor Expressed On Myeloid Cells 1，CD354 Antigen，Triggering Receptor Expressed on Myeloid Cells-1，TREM-1，TREM1，CD354，Triggering receptor expressed on monocytes 1
市販薬剤の数	0
治験薬の数	6
研究＆開発段階	Phase 2 Clinical

TREM-1 製品リスト

属性
Protein (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
Fc Tag (1)
マーカー
Unconjugated (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
TR1-H5251	Human	HEK293	Human TREM-1 / CD354 Protein, Fc Tag, low endotoxin

総数量1

お問い合わせ

TREM-1バックグランド

Triggering receptor expressed on myeloid cells 1 (TREM1) is also known as CD antigen CD354, and is a type I transmembrane protein with a single Ig-like domain. TREM1 is highly expressed in adult liver, lung and spleen than in corresponding fetal tissue. TREM-1 / CD354 stimulates neutrophil and monocyte-mediated inflammatory responses, and also triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock. TREM1 can interacts with TYROBP / DAP12.

TREM-1分子の別称

TREM1,CD354

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Nangibotide	LR-12	Phase 2 Clinical	Inotrem	Coronavirus Disease 2019 (COVID-19); Shock, Septic	詳細
ABBV-8736	ABBV-8736	Phase 2 Clinical	Abbvie Inc	Crohn Disease; Inflammatory Bowel Diseases	詳細
TREM-1 antibody (Boehringer Ingelheim)		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Autoimmune Diseases	詳細
CEL383	CEL-383	Phase 1 Clinical	Celsius Therapeutics Inc	Inflammatory Bowel Diseases	詳細
TREM 1 antibody(Boehringer Ingelheim International Gmbh)	TREM 1 antibody(Boehringer Ingelheim International Gmbh)	Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Immune System Diseases	詳細
PY-159	PY-159	Phase 1 Clinical	Centre for the Commercialization of Antibodies and Biologics	Neoplasms; Solid tumours	詳細